ReviewEcancermedicalscience2018
Pre-, pro- and synbiotics in cancer prevention and treatment-a review of basic and clinical research.
Review in Ecancermedicalscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): A systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Microbiome-gut-brain axis in cancer treatment-related psychoneurological toxicities and symptoms: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Consumption of a Leuconostoc holzapfelii-enriched synbiotic beverage alters the composition of the microbiota and microbial extracellular vesicles.Experimental & molecular medicine · 2019Trial
- Identification of a novel human gut microbes and microbial metabolites related genes signature for prognostic implication in head and neck squamous carcinomas.Discover oncology · 2026Article
- The Human Breast Microbiome: From Homeostasis to Malignancy, Mechanistic Insights and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- The Role of Lactobacillus Strain Probiotics in Breast Cancer: Strain-Specific Mechanisms and Therapeutic Potential Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
- Critical role of reproductive tract microbiota and derived metabolites in inflammation, tumor immunity, and tumorigenesis of gynecological cancers: a narrative review.Frontiers in immunology · 2026Review
- Role of Human Microbiome in Development and Management of Head and Neck Squamous Cell Carcinoma.Cancers · 2025Review
- The Influence of the Microbiome on the Complications of Radiotherapy and Its Effectiveness in Patients with Laryngeal Cancer.Cancers · 2024Article
- Review
- Article
- The role of diet in cancer: the potential of shaping public policy and clinical outcomes in the UK.Genes & nutrition · 2024Review
- Microbiome in radiotherapy: an emerging approach to enhance treatment efficacy and reduce tissue injury.Molecular medicine (Cambridge, Mass.) · 2024Review
- Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.Medical oncology (Northwood, London, England) · 2024Review
- Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?Frontiers in immunology · 2024Review
- Genetic heterogeneity of colorectal cancer and the microbiome.World journal of gastrointestinal oncology · 2023Review
- How to Improve Health with Biological Agents-Narrative Review.Nutrients · 2022Review
- Radiotherapy and the gut microbiome: facts and fiction.Radiation oncology (London, England) · 2021Review
- New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing appreciation of the role of the human microbiota in the pathophysiology of cancer. Pre-, pro- and synbiotics are some of the best evidenced means of manipulating the microbiota for therapeutic benefit and their potential role in the prevention and treatment of cancer has garnered significant interest. In this review, we discuss how these agents may have oncosuppressive effects by maintaining intestinal barrier function, immunomodulation, metabolism and preventing host cell proliferation. We highlight the epidemiological and trials-based evidence supporting a role for pre-, pro- and synbiotics in the prevention of cancer. Ultimately, there is more evidence in support of these agents as adjuncts in the treatment of cancer. We discuss their roles in optimising the efficacy and/or minimising the adverse effects of chemotherapy and radiotherapy, antibiotics and surgery. Although we see significant promise in the application of pre-, pro- and synbiotics for clinical benefit in oncology patients, the field is very much in its infancy and oncologists face substantial challenges in advising their patients appropriately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.